La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Sun Pharmaceutical Industries Gestione
Gestione criteri di controllo 4/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Dilip Shanghvi
Amministratore delegato
₹60.5m
Compenso totale
| Percentuale dello stipendio del CEO | 75.6% |
| Mandato del CEO | 31.5yrs |
| Proprietà del CEO | 9.6% |
| Durata media del management | 2.7yrs |
| Durata media del Consiglio di amministrazione | 3.3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now
Aug 24
Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next
Aug 06This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid
Jul 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth
Jun 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Jun 12Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 25Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Price Is Out Of Tune With Earnings
May 22Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Mar 13Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Feb 03Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today
Jan 05Getting In Cheap On Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Unlikely
Dec 18Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?
Oct 04Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?
Jul 03We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease
Jun 15Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?
Mar 14Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.50
Feb 03These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well
Dec 09Does This Valuation Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Imply Investors Are Overpaying?
Oct 13These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely
Sep 04Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Aug 05Estimating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
Jul 12Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?
Jun 02Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?
Apr 28Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | ₹104b |
| Mar 31 2024 | ₹61m | ₹46m | ₹96b |
| Dec 31 2023 | n/a | n/a | ₹89b |
| Sep 30 2023 | n/a | n/a | ₹85b |
| Jun 30 2023 | n/a | n/a | ₹84b |
| Mar 31 2023 | ₹55m | ₹41m | ₹85b |
| Dec 31 2022 | n/a | n/a | ₹42b |
| Sep 30 2022 | n/a | n/a | ₹41b |
| Jun 30 2022 | n/a | n/a | ₹39b |
| Mar 31 2022 | ₹51m | ₹38m | ₹33b |
| Dec 31 2021 | n/a | n/a | ₹64b |
| Sep 30 2021 | n/a | n/a | ₹62b |
| Jun 30 2021 | n/a | n/a | ₹60b |
| Mar 31 2021 | ₹46m | ₹35m | ₹29b |
| Dec 31 2020 | n/a | n/a | ₹24b |
| Sep 30 2020 | n/a | n/a | ₹15b |
| Jun 30 2020 | n/a | n/a | ₹7b |
| Mar 31 2020 | ₹43m | ₹32m | ₹38b |
| Dec 31 2019 | n/a | n/a | ₹40b |
| Sep 30 2019 | n/a | n/a | ₹43b |
| Jun 30 2019 | n/a | n/a | ₹30b |
| Mar 31 2019 | ₹263k | ₹1 | ₹27b |
| Dec 31 2018 | n/a | n/a | ₹34b |
| Sep 30 2018 | n/a | n/a | ₹24b |
| Jun 30 2018 | n/a | n/a | ₹36b |
| Mar 31 2018 | ₹34m | ₹28m | ₹21b |
Compensazione vs Mercato: La retribuzione totale di Dilip ($USD 721.24K ) è inferiore alla media delle aziende di dimensioni simili nel mercato Indian ($USD 1.21M ).
Compensazione vs guadagni: La retribuzione di Dilip è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Dilip Shanghvi (69 yo)
31.5yrs
Mandato
₹60,541,920
Compensazione
Mr. Dilip Shantilal Shanghvi serves as MD at Sun Petrochemicals Private Limited. He serves as Chairman of Board of Directors of Taro Pharmaceutical Industries Ltd at Taro Pharmaceuticals U.S.A., Inc. He se...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| MD & Chairman of the Board | no data | ₹60.54m | 9.6% ₹ 418.4b | |
| Executive VP | no data | ₹68.75m | 0.12% ₹ 5.2b | |
| Chief Financial Officer | 7.3yrs | ₹38.89m | Nessun dato | |
| Executive Vice-President of Global Operations | no data | Nessun dato | Nessun dato | |
| EVP & Chief Information Officer | less than a year | Nessun dato | Nessun dato | |
| VP, Head of Investor Relations & Strategic Projects | no data | Nessun dato | Nessun dato | |
| Company Secretary & Compliance Officer | 2.7yrs | Nessun dato | Nessun dato | |
| Director of Corporate Development | no data | ₹65.30m | Nessun dato | |
| Chief Human Resources Officer | less than a year | Nessun dato | Nessun dato | |
| Head of India Business | no data | Nessun dato | Nessun dato | |
| Chief Executive Officer of North America Business | 8.1yrs | Nessun dato | Nessun dato | |
| Head of Corporate Relations & CSR - India Regulatory Affairs | no data | Nessun dato | Nessun dato |
2.7yrs
Durata media
60yo
Età media
Gestione esperta: Il team dirigenziale di SUNPHARMA è considerato esperto (durata media dell'incarico 2.6 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| MD & Chairman of the Board | 31.5yrs | ₹60.54m | 9.6% ₹ 418.4b | |
| Executive VP | 1.3yrs | ₹68.75m | 0.12% ₹ 5.2b | |
| Non-Executive & Non-Independent Director | 30.7yrs | ₹2.20m | 1.8% ₹ 78.4b | |
| Non-Executive & Independent Director | 3.3yrs | ₹5.10m | Nessun dato | |
| Non-Executive Independent Director | 6.3yrs | ₹7.80m | Nessun dato | |
| Independent Director | 1.3yrs | ₹3.20m | Nessun dato | |
| Lead Independent Director | 3.3yrs | ₹8.50m | Nessun dato | |
| Independent Director | 1.8yrs | ₹4.80m | Nessun dato |
3.3yrs
Durata media
67.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di SUNPHARMA sono considerati esperti (durata media dell'incarico 3.3 anni).